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Currently, medications used in children are typically modified from pharmaceutical dosage forms 
designed for adults. Captopril is widely adapted to liquid formulations for use in hospitals. Its stability 
in the aqueous medium is reduced since it undergoes oxidation producing captopril disulfide (its main 
metabolite). The aim of this formulation study was to suggest favorable conditions for the development 
of a stable captopril formulation. The compatibility between the drug and excipients was evaluated by 
differential scanning calorimetry analysis (DSC). For studies in solution, different formulations were 
prepared according to a factorial design varying EDTA concentration, water purity and pH. The resultant 
formulations were stored at 60°C and analyzed over a twelve-day period using HPLC. The DSC curves 
obtained suggested, although not conclusive to elucidation, interactions of captopril with citric acid 
and sucralose. The stability study of these solutions revealed that the variables significantly influenced 
captopril content, which degraded at zero order kinetics and rates differing by a factor of up to 7 times, 
where pH proved the most influential factor. Interactions between variables were observed. Therefore, 
development of a stable captopril formulation is feasible provided EDTA and a buffering agent is used 
at suitable concentrations (0.08% and pH 3.85).
Keywords: Pediatric Formulation. Captopril/ pharmacokinetics. Thermal Analysis. Degradation Kinetics. 
Drug Stability. Drug Compounding/ utilization. Drug Utilization. Excipients/ pharmacokinetics. Dosage 
Forms. Drug Dosage Calculations. Kinetics. Enzyme Stability/drug effects. 
INTRODUCTION
The available medications are mostly developed for 
adults. Thus, the data on safe dose is often extrapolated 
for pediatric use. Children are subjected to therapy 
risk because they have different pharmacokinetic and 
pharmacodynamic mechanisms according to age and 
compared to adults (Rosa et al., 2006; OMS, 2007; 
Jadhav, Kern, 2010). The lack of accurate and adequate 
information on the use of pediatric medicines or the lack 
of appropriate formulations for the indicated dosages 
led to the spread of the term “therapeutic orphans” when 
referring to children (Permala et al., 2010).
Thus, non-specific medicines for children can 
be classified as off-label, used with a different age, 
dose, frequency, presentation, other delivery route or 
indication to label guidelines (Carvalho et al., 2003; 
Rose, 2005; Costa, Lima, Coelho, 2009); or unapproved, 
when contraindicated or not licensed for use in children, 
manipulated or modified in the hospital, and with no 
specific dosage for children (Carvalho et al., 2003).
In various studies, captopril, an inhibitor of angiotensin 
converting enzyme (ECA) (Ferreira, 1998; Katzung, 2005), 
was cited as a necessary medicament in liquid form for 
the treatment of childhood arterial hypertension and heart 
failure (Peterlini, Chaud, Pedreira, 2003; Standing, Tuleu, 
2005; Flores-Pérez, 2008; Santos et al., 2008; Costa, Lima, 
Coelho, 2009; Costa, Rey, Coelho, 2009). The problem of 
childhood hypertension has only received greater attention, 
so few medications have been developed and tested on 
children. Therefore, the antihypertensive treatment is 
initiated at dosages based on data obtained for adults 
(Salgado, Carvalhaes, 2003; Flynn, 2008).
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The development of a liquid formulation of captopril 
for pediatric use is challenging owing to its susceptibility 
to oxidative degradation facilitated by high humidity and 
catalyzed by metal traces commonly found in excipients 
(Marcatto et al., 2005). Moreover, these preparations 
must provide safe excipients and good palatability, as 
the medications mostly have a bitter, sour or salty taste 
(Hempenstall, Tuleu, 2009). 
Matthew, Das Gupta (1996) demonstrated that 
co-solvents, chelating agents and high concentrations 
of captopril favored the drug’s stability in aqueous 
systems. Schlatter, Sola, Saulnier (1997) evaluated the 
effect of pH and temperature on the stability of solutions 
at 1 mg/mL prepared from a captopril tablet of 25 mg. 
The solution prepared in citrate buffer at pH 5.0 was 
stable for at least 30 days at 4 °C. In extemporaneous oral 
liquid formulations at the same concentration containing 
antioxidants and chelating agents, pH did not influence 
the stability of captopril. However, samples stored at 
low temperatures were more stable and presented better 
microbiological quality (Escribano Garcia et al., 2005). 
Furthermore, studies have shown that a pH value in 
the acidic range and the addition of chelating agents 
(e.g. EDTA) retard the oxidation of captopril (Berger-
Gryllaki, 2007; Kristensen et al., 2008; Brustugun et al., 
2009).
Different conclusions arise from studies carried out 
under diverse conditions suggesting the influence of the 
factors on each other is complex. In this way, experimental 
planning such as factorial design has been applied as a 
powerful tool to understand the impact of formulation 
variables and preparation conditions on the stability 
and other properties of drug dosage forms (Padamwar, 
Pokharkar, 2006; Cekić et al., 2015). Besides, thermal 
analysis has been useful in pre-formulation studies 
to evaluate interactions between drug and excipients 
(Freire et al., 2009; Oliveira et al., 2011). 
Given that liquid preparation obtained by adapting 
the pharmaceutical dosage form (grinding of tablets 
followed by dispersion in a liquid medium) may result in 
inaccurate dosages and inadequate stability, jeopardizing 
the treatment, the aim of the present study was to evaluate 
the influence of interactions between pH, water quality and 
chelating agent concentration on the stability of captopril 
in the preparation of a pediatric formulation.
MATERIAL AND METHODS
Raw materials and solvents
•	 Captopril (Galena Química e Farmacêutica Ltda);
•	 EDTA (Isofar - Indústria e Comércio de Produtos 
Químicos Ltda);
•	 Anhydrous citric acid and dihydrate sodium citrate 
(Labsynth);
•	 Sucralose (Embrafarma Pharmaceutical Expertise); 
•	 Distilled water;
•	 Mineral water of the Indaiá brand (Composition: 
Chloride = 23.80 mg.L-1; Sodium = 14.99 mg.L-1; 
Nitrate = 2.9 mg.L-1; Bicarbonate = 0.80 mg.L-1; 
Sulfate = 0.8 mg.L-1; Potassium = 0.79 mg.L-1; 
Magnesium = 0.76 mg.L-1; Calcium = 0.23 mg.L-1; 
Barium = 0.027 mg.L-1; Strontium = 0.006 mg.L-1);
•	 For the preparation of the mobile phase used in the 
HPLC analysis: Methanol HPLC grade (VETEC 
Fine Chemicals Ltd), Phosphoric Acid 85% (Isofar 
- Industry and Chemicals Ltd) and ultra-pure water.
Study in solid phase (powder)
Determination of the drug-excipient compatibility
The compatibility between captopril and the 
excipients (EDTA, citric acid, dihydrate sodium citrate 
and sucralose) was measured by differential scanning 
calorimetry (DSC). The samples were obtained by 
physically mixing the drug and excipients at a proportion 
of 1:1 (m/m) with a spatula.
The DSC curves were obtained on a Shimadzu 
DSC-60 device, using aluminum pans with 2 mg of 
samples under atmospheric pressure of N2 at a flow rate of 
50 mL.min-1, heating rate of 10 °C.min-1 and temperature 
range of between 25 and 400 °C. 
In addition to the thermal analysis by DSC, the 
thermal behavior of captopril was evaluated by differential 
thermal analysis (DTA) and thermogravimetry (TG). 
Approximately 4 mg of the drug were placed in an alumina 
pan and analyzed on a Shimadzu DTG-60 device under 
an atmosphere of nitrogen at a flow rate of 50 mL.min-1, 
heating rate of 10 ºC.min-1 and temperature range of 
between 35 and 900 ºC. Both devices were calibrated 
with indium standards (melting point at 156 °C) and zinc 
(melting point at 420 °C).
Studies in liquid phase
Experimental design and statistical analysis
The formulations were developed using the 
minimum and maximum allowable concentration of 
EDTA, 0.005 and 0.1 % (m/v), respectively -1 and +1 
levels, according to the Handbook of Pharmaceutical 
Excipients, 6th ed. (Rowe, Sheskey, Quinn, 2009), in two 
types of water (distilled as lower level or -1, and mineral 
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- the highest level or +1) and at three pH values (2.5, 4.0 
and 5.5, corresponding to levels -1, 0 and +1 respectively). 
Therefore, 22x3 factorial planning was used, giving a total 
of 12 formulations, each in triplicate, with a final volume 
of 500 mL. The resultant formulations are shown in Table 
I. Captopril concentration was fixed at 5 mg/mL.
Furthermore, sucralose was added to the formulations 
as a sweetener, at variable concentrations according 
to the pH. The concentrations used were determined 
according to the subjective sensory analysis, where higher 
concentrations of the sweetener were required in more 
acidic formulations. The solutions were then subjected 
to heating in a QUIMIS oven (MODEL: Q-317 B252) at 
60 °C ± 2 °C and analyzed in alternate days for 12 days.
Captopril  was quantif ied according to the 
methodology contained in the Brazilian Farmacopeia, 
i.e. by high-performance liquid chromatography in a 
Shimadzu chromatograph, equipped with LC-10AT pump, 
ultraviolet detector (SPD-M20A5), DGU-20A5 degasser 
and PERKIN ELMER column with length of 250 mm 
and an internal diameter of 4.6 mm, packed with silica 
chemically bonded to an octadecylsilane group (5 μm), 
kept at ambient temperature and mobile phase flow rate 
of 1 mL.min-1. The mobile phase consisted of a mixture of 
phosphoric acid 0.11% (v/v) and methanol (45:55), filtered 
through an ALLCROM nylon membrane filter with pore 
size of 0.22 μm (Farmacopeia …, 2010).
The influence of the factors on the captopril content 
as a function of time was examined with the aid of the 
software Statistica 7.0, through Pareto diagrams (p=0.05); 
marginal means for analysis of interactions between 
factors; and response surface graphs, from which the best 
combination of factors to develop a stable formulation 
was established.
Evaluation of the degradation kinetics
Initially, captopril content data obtained over the 
12-day test period were plotted using Microsoft Excel 
2010 software to determine the order of the reaction. 
Data on the slope inclination, intercept and values of 
the coefficient of determination (R2) were derived from 
the equations applied for the zero, first and second order 
reactions (Florence, Attwood, 2003). Thus, the values 
of captopril content as a function of time were used, 
considering a direct linear relationship to zero order, the 
logarithmic function of the content versus the time to the 
first order, and in the case of the second order, inverse 
values of content as a function of time. The coefficients 
of determination (R2) derived were compared, considering 
the order of the reaction corresponding to the function for 
which the highest values were obtained.
Half-life (t½) time and the time taken for degradation 
of 10% of the drug (T90%) were also calculated, being 
defined as the validity period of the solution (Florence, 
Attwood, 2003).
RESULTS AND DISCUSSION
Studies in solid phase
Determination of the drug-excipient compatibility
The DSC, TG and DTA curves of captopril and DSC 
TABLE I - Formulations combining variables at different levels submitted to stress testing at 60 °C
Formulation [EDTA]% Type of water pH [Sucralose]%
Control - Distilled 2,73 -
Fa 0.005 Distilled 2.5 0.20
Fb 0.005 Distilled 4.0 0.17
Fc 0.005 Distilled 5.5 0.15
Fd 0.1 Distilled 2.5 0.20
Fe 0.1 Distilled 4.0 0.17
Ff 0.1 Distilled 5.5 0.15
Fg 0.005 Mineral 2.5 0.20
Fh 0.005 Mineral 4.0 0.17
Fi 0.005 Mineral 5.5 0.15
Fj 0.1 Mineral 2.5 0.20
Fk 0.1 Mineral 4.0 0.17
Fl 0.1 Mineral 5.5 0.15
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binary mixtures with the excipients used in this study are 
depicted in Figure 1. 
The DSC curve and the DTA of captopril (Figure 
1a) shows an endothermic event with a peak at 111.83 ºC 
(ΔHmelting = -135.24 J.g-1), corresponding to the melting 
of the drug. A second event starts around 200 °C and is 
related to drug decomposition. The TG curve shows that 
the decomposition occurs between 170 and 449 °C, in two 
steps, with a 97.21% decrease in the initial mass. 
In mixtures A (figure 1b) and C (Figure 1d), the 
thermal events for each substance alone were observed. 
Moreover, the enthalpy of the first peaks of mixtures A 
(ΔHmelting = -58.52 J.g-1) and C (ΔHmelting = -64.74 J.g-1) 
corresponded to approximately half the value of the 
melting peak of the drug, confirming the absence of 
interaction between captopril and excipients used in these 
mixtures: EDTA and dehydrate sodium citrate.
In mixture B (Figure 1c), the captopril melting 
point was reduced to 104.53 °C with broadening of the 
corresponding peak while the thermal event related to 
citric acid melting was not observed. However, the amount 
of energy involved in the captopril melting process (the 
first event observed on DSC curve of binary mixture) 
close to the value of the enthalpy involved in the melting 
of captopril (ΔH = -82.28 J.g-1) indicates no interaction 
between the components. Therefore, the DSC curve for 
mixture B suggests the dissolution of the citric acid in the 
molten captopril (Oliveira et al., 2011).
The DSC curve of the binary mixture between 
captopril and sucralose (Figure 1e) exhibited an 
exothermic event at 124 °C and ΔH = 29.64 J.g-1 while 
the thermal event related to sucralose at this temperature 
is endothermic (ΔHmelting = -74.01 J.g-1) characteristic of 
the melting of the substance. This change suggests an 
interaction between these components or dissolution of 
sucralose in the molten captopril.
Thermal analysis alone was not conclusive to 
elucidate if interactions between captopril and both 
citric acid and sucralose took place. Other methods 
should be used such as Infrared Spectrophotometry to 
understand the influence of those components in the solid 
state. Moreover, the results of the stress test provided 
later indicate that sucralose and citric acid were not 
determining factors for the decrease in captopril stability 
in the solutions.
Studies in liquid phase
Evaluation of stability of captopril solutions at 5 mglmL
The 12 formulations were subjected to the stress test 
and the captopril content was monitored by HPLC for a 
12-day period (peak at 4.0 minutes). A gradual decrease 
in captopril content was observed. According to Figure 2, 
the formulations with the lowest pH values (Fe, Fg, Fj 
and Fk) showed less variation in captopril content over 
the 12 days. Moreover, the Fc formulation stands out for 
the significant decrease in captopril content, showing poor 
stability. This solution was prepared at higher pH (5.5) 
and low concentrations of EDTA in distilled water, where 
these conditions appear to be the most unfavorable for the 
preparation of a stable oral solution of captopril.
In agreement with this observation, from the fourth 
day of analysis, the emergence of a peak can be noted 
on the chromatograms (tr = 6.2 min, probably captopril 
disulfide), a phenomenon most evident in the samples of 
the formulations at pH 5.5 (Fc, Ff, Fi and Fl).
In general, the formulations at pH 4.0 showed minor 
variations in captopril content, as did formulations at the 
same pH value containing the highest concentration of 
EDTA.
When calculating the coefficient of determination 
(R2) for reactions of zero, first and second order, the 
predominance of zero-order reactions was observed for 
all formulations together with the highest R2 values (Table 
II). Moreover, the R2 values were lower than the expected 
value (0.99), particularly in formulations with mineral 
water, probably due to the presence of ionic species 
in these solutions that can interact with metals able to 
accelerate the degradation of captopril (Pierangeli et al., 
2001).
Thus, in contrast to results reported by Berger-
Gryllaki et al. (2007), Kristensen et al. (2008) and Mathew, 
Das Gupta (1996), the rate of the decomposition reaction 
proved independent of captopril concentration, where the 
limiting factor, in this case, may have been temperature, 
as the formulations were stored in an oven at 60 °C. 
For a zero-order reaction, t½ and t90% are calculated 
by the equations 1 and 2 respectively:
  (equation 1)
  (equation 2)
where C0 is the initial concentration and k0 is the slope. The 
values of k0 correspond to the percentage of drug that is 
degraded with time (or degradation rate) and the intercept 
of the line at t=0 is equal to the initial concentration. 
The values of the degradation constant, half-life 
and shelf-life are shown in Table II. Analysis of these 
parameters confirms that formulations with a higher 
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FIGURE 1 – DSC, TG DTA and captopril curves (a) and DSC curves of excipients and their respective binary mixtures with the drug 
(b: EDTA and mixture A; c: citric acid and mixture B; d: dihydrate sodium citrate and mixture C; and e: sucralose and mixture D).
pH value (Fc, Ff, Fi and Fl) are less stable, showing 
degradation of 1.7 to 3.6 times faster than captopril alone. 
On the other hand, formulations prepared using 
mineral water as the solvent at pH 2.5 and 4.0 (Fg, Fh, 
Fj and Fk) resulted in less degradation than formulations 
prepared with distilled water. The Fk formulation 
(prepared with 0.1% of EDTA in mineral water at pH 
4.0) showed a lower rate of decomposition, resulting 
in higher stability of up to 15 days. The worst and 
best formulations concerning degradation rate (Fc and 
Fk respectively) differed by a factor of about 7 times. 
Kristensen et al. (2008) showed that captopril aqueous 
solutions at 5 mg/mL containing EDTA were more 
stable than those prepared at 1 mg/mL. The values 
found for t90% were 46 and 7 days respectively at 25°C. 
At temperature conditions closer to that used in this 
study, the degradation of captopril at 5 mg/mL resulted 
in constants around 9 x 10-3 days-1 at pH values below 4 
(Timmins, Jackson, Wang, 1982).
No evidence was found that sucralose influences 
captopril stability. Sucralose concentration was much 
lower in the solutions compared to the rate used in solid 
state study. Also, the solutions with higher sucralose 
concentration were those with lowest pH value, the higher 
stability provided was attributed to pH.
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Evaluation of the influence of pH, EDTA concentration 
and type of water on captopril content and interaction 
between factors
The influence of each variable, as well as their 
interactions, on captopril content are shown in a Pareto 
chart (Figure 3). The chart shows that pH influenced 
captopril content both positively and negatively. This 
is because captopril is a diprotic acid with pKa values 
of 3.7 and 9.8 relating to the carboxyl and thiol groups, 
respectively. Therefore, pH values above 3.7 promote 
ionization of the molecules, rendering them more reactive. 
However, degradation at a pH below 4.0 is independent 
of pH, where according to the Henderson-Hasselbalch 
equation, the thiol group is hardly ionized (Timmins, 
Jackson, Wang, 1982).
The type of water positively influenced captopril 
content probably due to the presence of different ionic 
species. The mineral water may have favored the stability 
of the compositions due to lower activity of metallic ions 
able to catalyze the oxidation of captopril, as they compete 
for the exchange site (Pierangeli et al., 2001).
The presence of metallic ions, such as iron and 
copper, increases the rate of oxidation of captopril 
since they act as catalysts in the oxidation reaction of 
the thiol group. These ions are contaminants usually 
found in the formulation excipients, packaging, caps 
and/or manufacturing equipment. For this reason, 
the EDTA is an interferent with a significant positive 
contribution to stability because it acts by sequestering 
metallic ions, as opposed to leaving them free to favor 
the degradation reaction of captopril (Timmins, Jackson, 
Wang, 1982).
Furthermore, the interaction between the factors 
is significant, since the influence of a specific variable 
depends on the level of the other, an effect seen in Figure 
4. Thus, the assessment of interactions between the 
EDTA concentration and the other variables confirms that 
raising the concentration of the chelating agent enhances 
the stability of solutions only when the other conditions 
are unfavorable, i.e. pH 5.5 and using distilled water. 
Therefore, for different levels of the water type variable, 
the concentration of the chelator has a different influence 
FIGURE 2 – Captopril content in the formulations submitted to 
60 °C over the 12-day period.
TABLE II - Linear regression coefficient values for zero order kinetic (R2), degradation rate (k0), half-life time (t½) and validity (t90%) 
of the analyzed formulations
Formulation R2 k0 (%.day-1) t½ (days) t90% (days)
Control* 0.8112 1.22 40.8 8.2
Fa 0.9619 1.81 27.6 5.5
Fb 0.9031 1.24 40.2 8.0
Fc 0.9018 4.37 11.4 2.3
Fd 0.9903 1.76 28.4 5.7
Fe 0.7074 0.72 69.2 13.8
Ff 0.9151 2.48 20.2 4.0
Fg 0.8251 0.75 67.0 13.4
Fh 0.7751 0.70 71.3 14.3
Fi 0.8789 2.07 24.1 4.8
Fj 0.7691 0.66 75.2 15.1
Fk 0.7009 0.64 77.7 15.5
Fl 0.9395 2.45 20.4 4.1
*captopril in aqueous solution (distilled water) 
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on the stability of the solution, showing the interaction 
between these factors (1Lby2L).
Regarding the relationship between water and pH, 
the type of water proved critical for the stability of the 
solutions at lowest pH values (2.5).
The surface response graphs (Figure 5) allow 
the optimal areas for the stability of captopril to be 
established. Figure 5a shows that a formulation with a pH 
near the central range of between 3.7 and 4.0, associated 
with an EDTA concentration of between 0.0525% and 
0.1%, with the loss of at most 10% of captopril may be 
obtained.
The optimum point in the surface response graph 
to the type of water x concentration of EDTA (Figure 
5b) is shifted to mineral water. Therefore, if mineral 
water associated with an EDTA concentration above 
0.0525% is used, there will be a smaller loss of captopril 
(maximum 10%). This result support the possibility of 
interaction of the ionic species in the mineral water with 
the metallic ions, once the chelating agent can be used in 
the low level. Meanwhile, extremes values of pH in the 
range studied (2.5 or 5.5) associated with distilled water 
favor the captopril degradation, being more evident in the 
higher pH range (Figure 5c), i.e. the central zone of the 
graph comprises an area of lesser degradation of captopril 
(90% content).
From the data on surface responses, it can be stated 
that to develop a stable formulation of captopril, EDTA 
at a concentration of 0.08% (m/v) and buffering agents 
(anhydrous citric acid and sodium citrate dihydrate) must 
be added to obtain a formulation with an approximate pH 
of 3.85. The indicated values correspond to the average 
values of the ranges in which higher stability of captopril 
was achieved.
CONCLUSIONS
Experimental planning was a useful tool to the 
pre-formulation study for the development of a liquid 
formulation of captopril. From the results of captopril 
contents obtained through the stress test, it can be stated 
that pH is the factor that has the most influence on the 
stability of the solutions. The type of water also has a 
significant influence, where mineral water improved 
the stability of captopril. Among these three factors, 
the concentration of EDTA has an important function in 
preserving the captopril content when associated with 
other interferents.
The surface response graphs revealed the 
components and their optimal concentrations required to 
maintain the stability of captopril, data which may be used 
in the development of future formulations for pediatric 
use. Based on the results of the response surface graphs it 
can be concluded that a solution containing 0.08% (m/v) 
of EDTA at a pH of 3.85 can be considered the basis for a 
more stable formulation of captopril.
FIGURE 3 - Pareto diagram of standardized effects of pH, type of water and EDTA concentration on the captopril degradation process.
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FIGURE 4 – Marginal means with confidence intervals (95%) for captopril content at different levels of the variables interfering 
the captopril degradation process: (a) EDTA; (b) water purity; (c) pH.
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